| http://www.w3.org/ns/prov#value | - The trial will provide the basis for evaluating MPCs in more advanced diabetes, to target complications including renal failure and cardiovascular disease.In addition, Mesoblast is planning a Phase II trial in the second half of 2013 to evaluate whether a single intravenous MPC injection can stabilize or reverse end-stage kidney disease in diabetics.In congestive heart failure, Mesoblast said it e
|
